Biological Information

Background Information:

Dopamine receptors belong to the superfamily of G protein-coupled seven transmembrane proteins. G-protein-coupled receptors constitute one of the major signal transduction systems in eukaryotic cells. Coding sequences for these receptors, in those regions believed to contribute to the agonist-antagonist binding site, are strongly conserved across mammalian species. Various members of the dopamine receptor family are generally classified as either ‘D1-like’ or ‘D2-like’. D2-like receptors comprise the D2, D3 and D4 receptors, which inhibit activation of adenylate cyclases via coupling to G1/G0 protein.

Family:

GPCR

Sub Family:

Dopamine

Class:

Class A

Protein Name:

D4

Uniprot Number:

P21917

Gene Name:

DRD4

Gene ID:

1815

Gene Aliases:

DRD1B

Accession Number:

NM_000797

Organism:

Human

Construct Details:

Recombinant

Cell Type:

CHO-K1

Assay Information

Assay Type:

Functional

Assay Sub Type:

Cell Based

Functional Mode:

Antagonist

Detection Method:

HTRF

Testing Information

Incubation:

10 min at 37°C

Control Inhibitor:

Clozapine

Control Activator:

dopamine (100 nM)

Test Concentration / Dose:

Eurofins will provide IC/EC50 calculation if 5 or more concentrations are selected.

Test Sample Requirements:

Minimum for 1) Screen: 60 µL of 10 mM stock -OR- 1 mg (pre-weighed) for 10µM finµL testing. 2) Dose Response: 90 µL of 10 mM stock -OR- 1 mg (pre-weighed) for a top concentration at 10 µM.

Minimum Order Quantity:

16

Turnaround Time

Standard:

15 Business Days

Reference Compound Data

PubChem ID

2818

Name

Clozapine

Measurement

168nM - IC50

PubChem ID

3559

Name

Haloperidol

Measurement

390nM - IC50

PubChem ID

5018

Name

SCH 23390

Measurement

- IC50

PubChem ID

5265

Name

Spiperone

Measurement

5.9nM - IC50

Clinical Relevance

Therapeutic Area:

CNS/Addiction/Pain

Adverse / Beneficial Action:

Dopamine D4 receptor antagonism may be useful in the treatment of psychosis, possibly without causing tardive dyskineasia and hyperprolactineamia; receptor antagonism has also been reported to reduce novelty seeking. No major pharmacological differences have been reported for the most common variants of this receptor (D4.2, D4.4 and D4.7).

Additional Information

Brand:

LeadHunter

Testing Location:

France - Celle L'Evescault

RELATED SOLUTIONS

Item: G017